These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1892365)

  • 1. Benefits of monitoring plasma levodopa in Parkinson's disease patients with drug-induced chorea.
    Sage JI; Mark MH; McHale DM; Sonsalla PK; Vitagliano D
    Ann Neurol; 1991 Jun; 29(6):623-8. PubMed ID: 1892365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.
    Zimmerman TR; Sage JI; Lang AE; Mark MH
    Mov Disord; 1994 Mar; 9(2):173-7. PubMed ID: 8196678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drenching sweats as an off phenomenon in Parkinson's disease: treatment and relation to plasma levodopa profile.
    Sage JI; Mark MH
    Ann Neurol; 1995 Jan; 37(1):120-2. PubMed ID: 7818245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of levodopa.
    Contin M; Martinelli P
    J Neurol; 2010 Nov; 257(Suppl 2):S253-61. PubMed ID: 21080186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and pharmacodynamic considerations in management of motor response fluctuations in Parkinson's disease.
    Cedarbaum JM
    Neurol Clin; 1990 Feb; 8(1):31-49. PubMed ID: 2181267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients].
    García de Yébenes J; Mateo D; Pino MA; Cordero M; Pastor M; Chacón J; Morales B; Sánchez V; Mena MA; Giménez Roldán S
    Neurologia; 1997 Apr; 12(4):145-56. PubMed ID: 9235023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.
    Yeh KC; August TF; Bush DF; Lasseter KC; Musson DG; Schwartz S; Smith ME; Titus DC
    Neurology; 1989 Nov; 39(11 Suppl 2):25-38. PubMed ID: 2685649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport.
    Nutt JG; Woodward WR; Hammerstad JP; Carter JH; Anderson JL
    N Engl J Med; 1984 Feb; 310(8):483-8. PubMed ID: 6694694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations.
    Deleu D; Jacques M; Michotte Y; Ebinger G
    Neurology; 1989 Nov; 39(11 Suppl 2):88-92; discussion 95. PubMed ID: 2685654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complex dystonia of Parkinson's disease: clinical features and relation to plasma levodopa profile.
    McHale DM; Sage JI; Sonsalla PK; Vitagliano D
    Clin Neuropharmacol; 1990 Apr; 13(2):164-70. PubMed ID: 2328507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired absorption of oral levodopa: a major cause for response fluctuations in Parkinson's disease.
    Djaldetti R; Ziv I; Melamed E
    Isr J Med Sci; 1996 Dec; 32(12):1224-7. PubMed ID: 9007159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease.
    Contin M; Martinelli P; Mochi M; Riva R; Albani F; Baruzzi A
    Mov Disord; 2005 Jun; 20(6):734-9. PubMed ID: 15747357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The response to levodopa in Parkinson's disease: imposing pharmacological law and order.
    Nutt JG; Holford NH
    Ann Neurol; 1996 May; 39(5):561-73. PubMed ID: 8619540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
    Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
    Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating motor fluctuations with controlled-release levodopa preparations.
    Koller WC; Pahwa R
    Neurology; 1994 Jul; 44(7 Suppl 6):S23-8. PubMed ID: 8047257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.
    Pahwa R; Lyons K; McGuire D; Silverstein P; Zwiebel F; Robischon M; Koller WC
    Mov Disord; 1997 Sep; 12(5):677-81. PubMed ID: 9380047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of Parkinson disease with levodopa depot preparations].
    Larsen JP; Nessler EG; Hestnes A; Vilming S; Holmsen R; Aksnes V; Johnson S; Brodtkorb E; Hunstad NA; Helle JR
    Tidsskr Nor Laegeforen; 1991 Oct; 111(26):3163-6. PubMed ID: 1948939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study.
    Stocchi F; Vacca L; Ruggieri S; Olanow CW
    Arch Neurol; 2005 Jun; 62(6):905-10. PubMed ID: 15956161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of early Parkinson's disease with controlled-release levodopa preparations.
    Rinne UK; Rinne JO
    Neurology; 1989 Nov; 39(11 Suppl 2):78-81; discussion 95. PubMed ID: 2586766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.